Ticker

Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the sixteen brokerages that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, five have issued a hold rating and ten have assigned a buy rating

PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) VP Mark Elliott Boulding sold 3,019 shares of the business's stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $69.48, for a total transaction of $209,760.12. Following the sale, the vice president directly owned 105,212 shares in the company,

WARREN, N.J., Feb. 23, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: TD Cowen 46th Annual Health Care Conference 2026 Monday, March 2 at 9:50 a.m.

PTC Therapeutics is transitioning its growth engine from legacy drugs to new launches like Sephience, targeting rare genetic diseases with high unmet need. Pipeline catalysts, notably Votoplam for Huntington's disease and Vatiquinone for Friedreich's ataxia, offer significant upside but carry clinical trial risks. PTCT's competitive edge lies in its oral small molecule platform, collaborative development model, and…

PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) CAO Christine Marie Utter sold 2,494 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $69.36, for a total value of $172,983.84. Following the completion of the sale, the chief accounting officer directly owned